Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
43
GSK Quote, Financials, Valuation and Earnings
Last price:
$50.38
Seasonality move
:
3.82%
Day range:
$50.36 - $50.81
52-week range:
$31.72 - $51.46
Dividend yield:
3.36%
P/E ratio:
14.37x
P/S ratio:
2.47x
P/B ratio:
4.66x
Volume:
3.9M
Avg. volume:
3.5M
1-year change:
49.3%
Market cap:
$101.3B
Revenue:
$40.1B
EPS (TTM):
$3.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$11.3B | $0.62 | 10.11% | 28.57% | $49.60 |
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.98 | 102.4% | -12.82% | $66.00 |
|
AZN
AstraZeneca PLC
|
$15.4B | $1.09 | 4.52% | 128.14% | $98.96 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -74.53% | $3.72 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$50.39 | $49.60 | $101.3B | 14.37x | $0.43 | 3.36% | 2.47x |
|
ANAB
AnaptysBio, Inc.
|
$44.67 | $66.00 | $1.2B | -- | $0.00 | 0% | 7.84x |
|
AZN
AstraZeneca PLC
|
$94.65 | $98.96 | $293.5B | 31.43x | $0.52 | 1.65% | 5.09x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.35 | $17.94 | $2M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$0.49 | $3.72 | $78.6M | -- | $0.00 | 0% | 154.38x |
|
NCNA
NuCana Plc
|
$3.37 | $104.00 | $14M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GSK
GSK Plc
|
52.36% | -0.215 | 27.67% | 0.53x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 0.355 | 41.03% | 8.52x |
|
AZN
AstraZeneca PLC
|
41.56% | 0.018 | 13.71% | 0.66x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
GSK Plc vs. Competitors
-
Which has Higher Returns GSK or ANAB?
AnaptysBio, Inc. has a net margin of 25.09% compared to GSK Plc's net margin of 19.8%. GSK Plc's return on equity of 42.84% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About GSK or ANAB?
GSK Plc has a consensus price target of $49.60, signalling downside risk potential of -1.58%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $66.00 which suggests that it could grow by 47.75%. Given that AnaptysBio, Inc. has higher upside potential than GSK Plc, analysts believe AnaptysBio, Inc. is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 ANABAnaptysBio, Inc.9 1 0 -
Is GSK or ANAB More Risky?
GSK Plc has a beta of 0.473, which suggesting that the stock is 52.665% less volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.317, suggesting its less volatile than the S&P 500 by 68.3%.
-
Which is a Better Dividend Stock GSK or ANAB?
GSK Plc has a quarterly dividend of $0.43 per share corresponding to a yield of 3.36%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or ANAB?
GSK Plc quarterly revenues are $11.5B, which are larger than AnaptysBio, Inc. quarterly revenues of $76.3M. GSK Plc's net income of $2.9B is higher than AnaptysBio, Inc.'s net income of $15.1M. Notably, GSK Plc's price-to-earnings ratio is 14.37x while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.47x versus 7.84x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.47x 14.37x $11.5B $2.9B ANABAnaptysBio, Inc.7.84x -- $76.3M $15.1M
-
Which has Higher Returns GSK or AZN?
AstraZeneca PLC has a net margin of 25.09% compared to GSK Plc's net margin of 16.69%. GSK Plc's return on equity of 42.84% beat AstraZeneca PLC's return on equity of 22.01%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B AZNAstraZeneca PLC73.89% $0.81 $78.6B -
What do Analysts Say About GSK or AZN?
GSK Plc has a consensus price target of $49.60, signalling downside risk potential of -1.58%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 4.55%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 AZNAstraZeneca PLC8 1 0 -
Is GSK or AZN More Risky?
GSK Plc has a beta of 0.473, which suggesting that the stock is 52.665% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.335, suggesting its less volatile than the S&P 500 by 66.49%.
-
Which is a Better Dividend Stock GSK or AZN?
GSK Plc has a quarterly dividend of $0.43 per share corresponding to a yield of 3.36%. AstraZeneca PLC offers a yield of 1.65% to investors and pays a quarterly dividend of $0.52 per share. GSK Plc pays 94.89% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or AZN?
GSK Plc quarterly revenues are $11.5B, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. GSK Plc's net income of $2.9B is higher than AstraZeneca PLC's net income of $2.5B. Notably, GSK Plc's price-to-earnings ratio is 14.37x while AstraZeneca PLC's PE ratio is 31.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.47x versus 5.09x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.47x 14.37x $11.5B $2.9B AZNAstraZeneca PLC5.09x 31.43x $15.1B $2.5B
-
Which has Higher Returns GSK or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About GSK or BDRX?
GSK Plc has a consensus price target of $49.60, signalling downside risk potential of -1.58%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7468.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than GSK Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is GSK or BDRX More Risky?
GSK Plc has a beta of 0.473, which suggesting that the stock is 52.665% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock GSK or BDRX?
GSK Plc has a quarterly dividend of $0.43 per share corresponding to a yield of 3.36%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or BDRX?
GSK Plc quarterly revenues are $11.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, GSK Plc's price-to-earnings ratio is 14.37x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.47x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.47x 14.37x $11.5B $2.9B BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns GSK or MREO?
Mereo BioPharma Group Plc has a net margin of 25.09% compared to GSK Plc's net margin of -2923.31%. GSK Plc's return on equity of 42.84% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About GSK or MREO?
GSK Plc has a consensus price target of $49.60, signalling downside risk potential of -1.58%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.72 which suggests that it could grow by 652.81%. Given that Mereo BioPharma Group Plc has higher upside potential than GSK Plc, analysts believe Mereo BioPharma Group Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 MREOMereo BioPharma Group Plc4 2 0 -
Is GSK or MREO More Risky?
GSK Plc has a beta of 0.473, which suggesting that the stock is 52.665% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock GSK or MREO?
GSK Plc has a quarterly dividend of $0.43 per share corresponding to a yield of 3.36%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or MREO?
GSK Plc quarterly revenues are $11.5B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, GSK Plc's price-to-earnings ratio is 14.37x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.47x versus 154.38x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.47x 14.37x $11.5B $2.9B MREOMereo BioPharma Group Plc154.38x -- -- -$7M
-
Which has Higher Returns GSK or NCNA?
NuCana Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About GSK or NCNA?
GSK Plc has a consensus price target of $49.60, signalling downside risk potential of -1.58%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 617110.68%. Given that NuCana Plc has higher upside potential than GSK Plc, analysts believe NuCana Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 NCNANuCana Plc0 1 0 -
Is GSK or NCNA More Risky?
GSK Plc has a beta of 0.473, which suggesting that the stock is 52.665% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock GSK or NCNA?
GSK Plc has a quarterly dividend of $0.43 per share corresponding to a yield of 3.36%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or NCNA?
GSK Plc quarterly revenues are $11.5B, which are larger than NuCana Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than NuCana Plc's net income of -$378.9K. Notably, GSK Plc's price-to-earnings ratio is 14.37x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.47x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.47x 14.37x $11.5B $2.9B NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
